StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Somil Mehta, Sharekhan

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))28 Sept 2026via CNBC Awaaz.

Entry₹1,958.7Inferred
Target₹2,050
Total upside +4.66% (call closed)
Stop loss₹1,870-4.53% risk
Exit₹1,87030 Sept 2026, 9:35 am
Stop-loss hit-4.53%
Follow Somil Mehta for new calls(26% target hit, 293 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 1 active Swing call on LALPATHLABSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Sept 2026
5 supporting0 opposing
Supports the BUY call (5)

Dr. Lal PathLabs Ltd announces the completion of its acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, through its wholly-owned subsidiary DLPL Dubai. Sunshine Healthcare Limited is n

BSE · Company Update·26 Sept · 3d ago

(opens in new tab)

Dr. Lal Path Labs Ltd. approved the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. SN Genelab will become a subsidiary.

NSE · Outcome of Board Meeting·24 Sept · 5d ago

(opens in new tab)

Dr. Lal PathLabs Ltd announced board approval for the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. This acquisition aims to strengt

BSE · Company Update·24 Sept · 5d ago

(opens in new tab)

Dr. Lal PathLabs Ltd announced board approval for the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance-linked earn out. SN Genelab will become a subsidi

BSE · Others·24 Sept · 5d ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·19 Aug · 1mo ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Somil Mehta, Sharekhan

Every call and its outcome